Improved Treatment of Pancreatic Cancer with Drug Delivery Nanoparticles Loaded with a Novel AKT/PDK1 Inhibitor

Pancreas

Volumn 45, Issue 8, 2016, Pages 1158-1166

  Kobes, Joseph E ^a,b   Daryaei, Iman ^c   Howison, Christine M ^d   Bontrager, Jordan G ^a   Sirianni, Rachael W ^e   Meuillet, Emmanuelle J ^f   Pagel, Mark D ^f,g  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNITED STATES MILITARY ACADEMY   (United States)

^c University of Arizona   (United States)

^d University of Arizona   (United States)

^e BARROW NEUROLOGICAL INSTITUTE   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

AKT PDK1 inhibitor; apparent diffusion coefficient (ADC); magnetic resonance imaging (MRI); pancreatic cancer; poly(lactic co glycolic) acid nanoparticles (PLGA)

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE; PHT 427; POLYGLACTIN; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG; LACTIC ACID; POLYGLYCOLIC ACID; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DELAYED DRUG RELEASE; DIFFUSION WEIGHTED IMAGING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ISOLATION; EMULSION; EX VIVO STUDY; FLUORESCENCE IMAGING; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NANOENCAPSULATION; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; STATIC ELECTRICITY; TREATMENT DURATION; TUMOR VOLUME; ZETA POTENTIAL; ANIMAL; PANCREAS TUMOR; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; LACTIC ACID; MICE; NANOPARTICLES; PANCREATIC NEOPLASMS; POLYGLYCOLIC ACID; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TISSUE DISTRIBUTION;

EID: 84959244390     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000607     Document Type: Article

References (54)

1. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg. 1998;383:129-133.
2. Kindler HL. Front-line therapy of advanced pancreatic cancer. Semin Oncol. 2005;32:S33-S36.
3. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115:665-672.
4. Xu Q, Zhang TP, Zhao YP. Advances in early diagnosis and therapy of pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2011;10:128-135.
5. Di Costanzo F, Sdrobolini A, Gasperoni S. Possibilities of palliation in pancreatic cancer. Tumori. 1999;85:S47-S53.
6. Sato N, Yamabuki T, Takano A, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010;70:5326-5336.
7. Yang Q, Williams D, Owusu-Ababio G, et al. Controlled release tacrine delivery system for the treatment of Alzheimer's disease. Drug Deliv. 2001; 8:93-98.
8. Vasir JK, Labhasetwar V. Biodegradable nanoparticles. In: Friedman T, Rossi J, eds. Gene Transfer: Delivery and Expression of DNA and RNA. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2007: 561-566.
9. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3: 1377-1397.
10. McCall RL, Sirianni RW. PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS. J Vis Exp. 2013;82:51015.
11. Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15:517-535.
12. Householder KT, DiPerna DM, Chung EP, et al. Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma. Int J Pharm. 2015;479:374-380.
13. Sánchez E, Baro M, Soriano I, et al. In vivo-in vitro study of biodegradable and osteointegrable gentamicin bone implants. Eur J Pharm Biopharm. 2001;52:151-158.
14. Jiang G, Qiu W, DeLuca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Pharm Res. 2003;20:452-459.
15. Onoue S, Kuriyama K, Uchida A, et al. Inhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity. Pharm Res. 2011;28:1157-1166.
16. Lam XM, Duenas ET, Daugherty AL, et al. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release. 2000;67:281-292.
17. Cohen-Sela E, Chorny M, Koroukhov N, et al. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release. 2009;133:90-95.
18. Moses SA, Ali MA, Zuohe S, et al. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res. 2009;69:5073-5081.
19. Meuillet EJ, Zuohe S, Lemos R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010;9:706-717.
20. Kim H, Morgan DE, Buchsbaum DJ, et al. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res. 2008;68:8369-8376.
21. Awotwe-Otoo D, Zidan AS, Rahman Z, et al. Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies. AAPS PharmSciTech. 2012;13:611-622.
22. Tewes F, Munnier E, Antoon B, et al. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm. 2007;66: 488-492.
23. Abdelghany SM, Schmid D,Deacon J, et al. Enhanced antitumor activity of the photosensitizer meso-Tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles. Biomacromolecules. 2013;14:302-310.
24. McCarron PA, Marouf WM, Quinn DJ, et al. Antibody targeting of camptothecin-loaded PLGA nanoparticlesto tumor cells. Bioconjug Chem. 2008;19:1561-1569.
25. Meuillet EJ, Mania-Farnell B, George D, et al. Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431. Exp Cell Res. 2000;256:74-82.
26. Kranz H, Bodmeier R. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Eur J Pharm Sci. 2008;34:164-172.
27. Vasir JK, Labhasetwar V. Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials. 2008;29:4244-4252.
28. Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res. 2009;26:2588-2598.
29. Wendt MK, MolterJ, Flask CA, et al. Invivo dual substrate bioluminescent imaging. J Vis Exp. 2011;56:3245.
30. Damaraju VL, Bouffard DY, Wong CK, et al. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer. 2007;7:121.
31. Lucero-Acuña A, Jeffery JJ, Abril ER, et al. Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer. Int J Nanomedicine. 2014;9:5653-5665.
32. Li W, Zhang Z, Nicolai J, et al. Magnetization transfer MRI in pancreatic cancer xenograft models. Magn Reson Med. 2012;68: 1291-1297.
33. Hagmann P, Jonasson L, Maeder P, et al. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics. 2006;26: S205-S223.
34. O'Donnell LJ, Westin CF. An introduction to diffusion tensor image analysis. Neurosurg Clin N Am. 2011;22:185-196.
35. Gaumet M, Gurny R, Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur J Pharm Sci. 2009;36:465-473.
36. Fei B, Wang H, Muzic RF Jr, et al. Deformable and rigid registration of MRI and microPET images for photodynamic therapy of cancer in mice. Med Phys. 2006;33:753-760.
37. Böcker R, Estler CJ. A high pressure liquid chromatographic method for the determination of tetracyclines in blood and organs of experimental animals. Arzneimittelforschung. 1979;29:1690-1693.
38. Leitner A, Zöllner P, Lindner W. Determination of the metabolites of nitrofuran antibiotics in animal tissue by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2001;939:49-58.
39. Mu L, Teo MM, Ning HZ, et al. Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system. J Control Release. 2005; 103:565-575.
40. Li D, Yamamoto H, Takeuchi H, et al. A novel method for modifying AFM probe to investigate the interaction between biomaterial polymers (chitosan-coated PLGA) and mucin film.Eur J Pharm Biopharm. 2010;75: 277-283.
41. Luo R, Venkatraman SS, Neu B. Layer-by-layer polyelectrolyte-polyester hybrid microcapsules for encapsulation and delivery of hydrophobic drugs. Biomacromolecules. 2013;14:2262-2271.
42. Fortunati E, Mattioli S, Visai L, et al. Combined effects of Ag nanoparticles and oxygen plasma treatment on PLGA morphological, chemical, and antibacterial properties. Biomacromolecules. 2013;14:626-636.
43. Fotaki N, Vertzoni M. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations. Open Drug Delivery J. 2010;4:2-13.
44. Allison SD. Analysis of initial burst in PLGA microparticles. Expert Opin Drug Deliv. 2008;5:615-628.
45. Schoennagel BP, Habermann CR, Roesch M, et al. Diffusion-weighted imaging of the healthy pancreas: apparent diffusion coefficient values of the normal head, body, and tail calculated from different sets of b-values. J Magn Reson Imaging. 2011;34:861-865.
46. Herrmann J, Schoennagel BP, RoeschM,et al. Diffusion-weighted imaging of the healthy pancreas: ADC values are age and gender dependent.J Magn Reson Imaging. 2013;37:886-891.
47. Wang DQ, Zeng MS, Shi X, et al. Comparison of MRI manifestations and histopathologic findings in pancreatic head carcinoma in vivo ex vivo. Zhonghua Zhong Liu Za Zhi. 2008;30:347-351.
48. Kim S, Pickup S, Hsu O, et al. Diffusion tensor MRI in rat models of invasive and well-demarcated brain tumors. NMR Biomed. 2008;21: 208-216.
49. Jansen SA, Conzen SD, Fan X, et al. In vivo MRI of early stage mammary cancers and the normal mouse mammary gland. NMR Biomed. 2011;24: 880-887.
50. Montelius M, Ljungberg M, Horn M, et al. Tumour size measurement in a mouse model using high resolution MRI. BMC Med Imaging. 2012;12:12.
51. Higuchi Y, Herrera P, Muniesa P, et al. Expression of a tumor necrosis factor alpha transgene in murine pancreatic beta cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med. 1992; 176:1719-1731.
52. Kawakami Y, Inoue K, Hayashi H, et al. Subcutaneous xenotransplantation of hybrid artificial pancreas encapsulating pancreatic B cell line (MIN6): functional and histological study. Cell Transplant. 1997;6:541-545.
53. Casanova ML, Bravo A, Ramírez A, et al. Exocrine pancreatic disorders in transsgenic mice expressing human keratin 8. J Clin Invest. 1999;103: 1587-1595.
54. Spector I, Zilberstein Y, Lavy A, et al. Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice. PLoS One. 2012;7:e41833.